Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer

<p>Colorectal Cancer (CRC) is a highly heterogeneous group of diseases, with distinctive genetic and epigenetic alterations. CRC tumors bearing KRAS or BRAF mutations still remain resistant to new therapies. Thus, this augments the necessity to reveal new therapeutic targets in mutKRAS/BRAF, which may account for up to 50% of the total CRC patients. To this end, we investigated primary untreated CRC tumors (WES &amp; RNA-Seq) from 28 Greek patients for their systematic molecular characterization and stratification into diverse groups based on their microsatellite instability (MSI) status and KRAS/BRAF genetic variations, in order to unravel novel targets and putative personalized treatment interventions. The raw data of this project (WES &amp; RNA-Seq) have been uploaded in the EGA European Genome-Phenome Archive (EGAD00001011262 and EGAD00001011263).</p>